GlobeNewswire (May 8, 2013)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
228 people get MNOV articles and Market Currents by email alert.
Get email alerts on MNOV »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (Mar 28, 2013)
-
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Dec 9, 2012)
-
GlobeNewswire (Nov 18, 2012)
-
GlobeNewswire (Nov 14, 2012)
-
GlobeNewswire (Nov 12, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Oct 25, 2012)
-
GlobeNewswire (Oct 22, 2012)
-
GlobeNewswire (Sep 4, 2012)
-
GlobeNewswire (Aug 28, 2012)
-
GlobeNewswire (Aug 20, 2012)
-
GlobeNewswire (Aug 9, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
MediciNova Acquiring Avigen: A Post-MortemGreenbackd • Mon, Aug 24, 2009
-
Biotech Dealmaking Takes a Summer BreatherThe Burrill Report • Sun, Aug 23, 2009 -
-
Avigen: Proposed Merger with MediciNova Back on the TableGreenbackd • Tue, Jul 21, 2009
-
21 Net / Net Index Completes First YearJon Heller • Sun, Feb 15, 2009 -
-
Top 10 Net/Nets by Market CapitalizationJon Heller • Thu, Sep 20, 2007
There are no Transcripts on MNOV.
-
GlobeNewswire (May 8, 2013)
-
GlobeNewswire (Mar 28, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
GlobeNewswire (Dec 9, 2012)
-
GlobeNewswire (Nov 18, 2012)
-
GlobeNewswire (Nov 14, 2012)
-
GlobeNewswire (Nov 12, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Nov 7, 2012)
-
GlobeNewswire (Oct 25, 2012)
-
GlobeNewswire (Oct 22, 2012)
-
GlobeNewswire (Sep 4, 2012)
-
GlobeNewswire (Aug 28, 2012)
-
GlobeNewswire (Aug 20, 2012)
-
GlobeNewswire (Aug 9, 2012)
MNOV vs. ETF Alternatives
Company Description
Currently, there's no company description for MNOV.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Thursday, May 9, 12:46 PM
Midday top 10 gainers: TRMD +94%. OPTT +42%. VRML +32%. AFFY +28%. TSLA +27%. XOMA +26%. GMCR +25%. CTRP +24%. OWW +23%. CHYR +19%.
Midday top 10 losers: LPSN -34%. PZZI -33%. RAX -26%. KEM -25%. NSYS -23%. MNOV -22%. WG -20%. GV -18%. ORBT -16%. OFIX -16%. Comment! [On the Move] -
Wednesday, May 1, 12:50 PM
Midday top 10 gainers: IQNT +60%. BCOV +31%. CNIT +28%. MNOV +21%. MSPD +19%. SONS +15%. TRLA +15%. RATE +15%. REGN +14%. SGI +14%.
Midday top 10 losers: ACCL -21%. RBC -20%. ESBF -17%. LEDS -16%. KFRC -15%. AGN -14%. CRAY -13%. ASTX -13%. XXIA -13%. UTI -12%. Comment! [On the Move] - Thursday, March 28, 5:37 PM MedicNova (MNOV): Q4 EPS of -$0.14 in-line. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Friday, March 1, 1:01 PM
Midday top 10 gainers: GMXR +56%. RVLT +37%. MTG +24%. ANAC +15%. DECK +14%. NSPH +13%. KERX +13%. ATEC +13%. CRIS +12%. CIDM +12%.
Midday top 10 losers: SCMR -73%. AT -29%. RNIN -23%. LTBR -23%. FWLT -17%. MDR -14%. SUP -13%. SHIP -13%. MNOV -12%. CBMX -12%. Comment! [On the Move] -
Thursday, February 28, 9:10 AM
Premarket gainers: MNOV +11%. BDBD +10%. RTK +8%. ZGNX +7%. NEO +7%. NBG +6%.
Losers: GRPN -29%. BSFT -23%. JCP -16%. PKT -15%. MTG -14%. MCP -8%. CWH -7%. 1 Comment [On the Move] - Wednesday, February 27, 11:54 AM MediciNova (MNOV) tacks on an additional 12.4% gain from yesterday's big move, after the company said its MN-166 drug treatment for methamphetamine dependence has been granted fast-track status by the FDA. Comment! [Healthcare, On the Move]
-
Tuesday, February 26, 12:45 PM
Midday top 10 gainers: MNOV +54%. RNIN +45%. CWH +31%. SLCA +22%. ALC +22%. NOAH +16%. GMXR +14%. PRPH +13%. EMITF +13%. FLML +12%.
Midday top 10 losers: FSGI -25%. HSII -20%. VRTB -19%. VSI -18%. TWI -16%. SSP -13%. ENMD -12%. VVUS -12%. VIPS -10%. CHMT -10%. Comment! [On the Move] - Tuesday, February 26, 9:15 AM MediciNova (MNOV) +23.8% premarket after announcing its MN-166 drug as a treatment for methamphetamine dependence was granted fast-track status by the FDA. Comment! [Healthcare, On the Move]
-
Friday, December 28, 2012, 12:45 PM
Midday top 10 gainers: TRIT +57%. AMPL +22%. AEZS +16%. LDK +13%. SOQ +13%. YONG +13%. PAMT +11%. ABCD +11%. MNOV +10%. MNGA +10%.
Midday top 10 Losers: ISSC -31%. BAGL -26%. FSGI -15%. PLBC -14%. BOSC -13%. OMER -11%. AMBO -9%. MOC -8%. SMED -8%. PRIS -8%. Comment! [On the Move] - Monday, November 12, 2012, 6:57 PM MediciNova (MNOV) publishes positive Phase 2 results for its asthma study, MN-221, in the Journal of Asthma. MN-221 is designed to treat acute asthmatic episodes through an intravenous infusion, which bypasses constricted airways to deliver the drug directly to the lungs. The tests showed a positive lung response without an accompanying increase in heart rate - which is a major concern - when the drugs were administered. Comment! [Healthcare]
- Thursday, August 23, 2012, 7:46 PM MedicNova (MNOV) reports positive results from Phase 1b trials of its pulmonary disease treatment MN-221. The company says the majority of the subjects completed the study and there were no clinically significant safety concerns. In addition, preliminary pharmacokinetic and efficacy findings were encouraging. Shares -2.4% AH. Comment! [Healthcare]
-
Thursday, May 24, 2012, 9:05 AM
Premarket gainers: KUTV +34%. P +19%. CLDX +9%. HPQ +8%. GALE +6%.
Losers: MNOV -52%. NTAP -13%. SIG -9%. TIF -8%. Comment! [On the Move] - Wednesday, May 23, 2012, 5:21 PM MediciNova (MNOV) -45.1% AH after announcing preliminary results from a Phase 2b clinical study failed to show significant improvement for patients treated with its MN-221 asthma treatment. Comment! [Healthcare, On the Move]
- Monday, April 23, 2012, 7:10 PM MediciNova (MNOV) says it's received a Notice of Allowance from the Australian Government Patent Office for an application that covers the use of ibudilast for the treatment of multiple forms of chronic neuropathic pain. Ibudilast is the company's lead drug development candidate for certain neurological conditions, including progressive forms of multiple sclerosis, neuropathic pain and drug addiction. Shares +4.1% AH. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
Joe Springer
Alfred is the Mann! $MNKD $AMRN $MNOV $PCRX $PPHM $PSDV $SVNT #biotech #pharma #stocks #finance #speculation http://seekingalpha.com/a/h4r3 - View all 0 replies
-
Scott Matusow
I will be live on my show most of the day @ http://bit.ly/xP8ArD to discuss $MNOV and $CLDX log on and listen and chat with me. - View all 2 replies
-
Bob de'Long: I'll be live all day also, but will be incommunicado, except to beautiful women. -
Cdonecker: I am unable to listen at work, If you could summarize your thoughts here later that would be great!
-
Scott Matusow
$MNOV = another successful call from me, just hit $3.75, $SNSS will be as well in my opinion, just give it some time. - View all 18 replies
-
-
Scott Matusow: yes, it should unless market tanks in my opinion. I am confident of hitting my short term target on it.
-
Scott Matusow
There goes $MNOV like I told you guys. as it gets closer to data release, expect it to run higher to around 3.50, maybe higher in my opinion - View all 5 replies
-
-
-
Scott Matusow
I expect $MNOV increase volume and tighter spread over time as it gets closer to catalyst dates. Nice opp with that one - View all 6 replies
-
captainsaino: Nice call with MNOV. I got in late yesterday at $2.83, wish I had more cash,but I am all in on ATRS. -
-
Scott Matusow
$MNOV will see a run-up soon, $ARNA will also resume its run-up. Care to wager me on these 2? - View all 9 replies
-
Scott Matusow: I don't get super deep with my articles. Lot's of great authors on SA, but too much focus on exaction of product detail. fine, but
-
Scott Matusow: We trade stocks, to make money right? That's what I focus on. products can be great, but if financial&stock structure sucks, pps sucks
-
Scott Matusow
In case some of you feel bad with $MNOV, my pops likes to trade from time to time and he is buying some - View all 6 replies
-
-
-
Scott Matusow
I guess I need to give picks that move 30 cents a day on tons of volume, lol! Watch and see on $MNOV - View all 0 replies
-
Scott Matusow
Don't like my $MNOV pick ay? You will when its closer to DATA release end of May which should be positive - View all 0 replies
LATEST REPLIES
-
Scott Matusow
I will be live on my show most of the day @ http://bit.ly/xP8ArD to discuss $MNOV and $CLDX log on and listen and chat with me. - View all 2 replies
-
Bob de'Long: I'll be live all day also, but will be incommunicado, except to beautiful women.
-
Cdonecker: I am unable to listen at work, If you could summarize your thoughts here later that would be great!
-
Scott Matusow
$MNOV = another successful call from me, just hit $3.75, $SNSS will be as well in my opinion, just give it some time. - View all 18 replies
-
-
Scott Matusow: yes, it should unless market tanks in my opinion. I am confident of hitting my short term target on it.
-
Scott Matusow
There goes $MNOV like I told you guys. as it gets closer to data release, expect it to run higher to around 3.50, maybe higher in my opinion - View all 5 replies
-
-
-
Scott Matusow
$MNOV will see a run-up soon, $ARNA will also resume its run-up. Care to wager me on these 2? - View all 9 replies
-
Scott Matusow: I don't get super deep with my articles. Lot's of great authors on SA, but too much focus on exaction of product detail. fine, but
-
Scott Matusow: We trade stocks, to make money right? That's what I focus on. products can be great, but if financial&stock structure sucks, pps sucks
-
Scott Matusow
I expect $MNOV increase volume and tighter spread over time as it gets closer to catalyst dates. Nice opp with that one - View all 6 replies
-
captainsaino: Nice call with MNOV. I got in late yesterday at $2.83, wish I had more cash,but I am all in on ATRS.
-
-
Scott Matusow
In case some of you feel bad with $MNOV, my pops likes to trade from time to time and he is buying some - View all 6 replies
-
-
-
Scott Matusow
Either tomorrow or next day,$ MNOV to be mentioned as a catalyst trade. Phase 2b results by the end of May acute exacerbations of asthma - View all 2 replies
-
-
Scott Matusow: yep, nice move, tells me something might be coming news wise there.
-
Scott Matusow
after $MNOV, and another ASCO trade, considering taking a break from writing about catalyst trades, more focus on long term investments. - View all 5 replies
-
-
